Reports Q1 revenue $88.71M, consensus $86.95M. “We ended the first quarter of fiscal 2025 with our eighth consecutive quarter of revenue growth and continued improvement in gross margin. We’re starting the fiscal year strong, demonstrating our unwavering commitment to progressing toward adjusted EBITDA breakeven,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
Questions or Comments about the article? Write to editor@tipranks.com